ADC Therapeutics Shares Plummet on Lymphoma Drug Trial Data, Possible Cost Cuts

Dow Jones

Jun 04

By Elias Schisgall

Shares of ADC Therapeutics plummeted after the company said it may pursue near-term cost cuts after reporting data from a Phase 3 trial of a lymphoma treatment.

Shares fell 38% to $1.90 in after-hours trading Wednesday. The stock closed down 2.8% at $3.08, down 13% this year.

The company said Zynlonta in combination with rituximab achieved statistical significance on the primary endpoint of progression-free survival, without any detrimental effect on a secondary endpoint of overall survival. The treatment also led to a higher complete response rate and duration.

The test arm saw a similar rate of Grade 3 treatment emergent adverse events but a higher rate of Grade 5 TEAEs, serious adverse events, and side effects that led to study drug withdrawal.

"In the context of a positive study, based on the totality of the data, we plan to discuss the benefit-risk profile of this combination with the U.S. FDA as we prepare for the planned supplemental biologics license application filing," Chief Executive Ameet Mallik said.

The company also said it will "continue to evaluate a broad range of value maximizing alternatives," including near-term cost reductions.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

June 03, 2026 16:53 ET (20:53 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2640841431"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640841431\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640841431?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 04:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640841431","market":"other","top_or_hot":-1,"title":"ADC Therapeutics Shares Plummet on Lymphoma Drug Trial Data, Possible Cost Cuts","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plummeted after the company said it may pursue near-term cost cuts after reporting data from a Phase 3 trial of a lymphoma treatment. \n</p>\n<p>\n  Shares fell 38% to $1.90 in after-hours trading Wednesday. The stock closed down 2.8% at $3.08, down 13% this year. \n</p>\n<p>\n  The company said Zynlonta in combination with rituximab achieved statistical significance on the primary endpoint of progression-free survival, without any detrimental effect on a secondary endpoint of overall survival. The treatment also led to a higher complete response rate and duration. \n</p>\n<p>\n  The test arm saw a similar rate of Grade 3 treatment emergent adverse events but a higher rate of Grade 5 TEAEs, serious adverse events, and side effects that led to study drug withdrawal. \n</p>\n<p>\n  \"In the context of a positive study, based on the totality of the data, we plan to discuss the benefit-risk profile of this combination with the U.S. FDA as we prepare for the planned supplemental biologics license application filing,\" Chief Executive Ameet Mallik said. \n</p>\n<p>\n  The company also said it will \"continue to evaluate a broad range of value maximizing alternatives,\" including near-term cost reductions. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2026 16:53 ET (20:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADC Therapeutics Shares Plummet on Lymphoma Drug Trial Data, Possible Cost Cuts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADC Therapeutics Shares Plummet on Lymphoma Drug Trial Data, Possible Cost Cuts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-04 04:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plummeted after the company said it may pursue near-term cost cuts after reporting data from a Phase 3 trial of a lymphoma treatment. \n</p>\n<p>\n  Shares fell 38% to $1.90 in after-hours trading Wednesday. The stock closed down 2.8% at $3.08, down 13% this year. \n</p>\n<p>\n  The company said Zynlonta in combination with rituximab achieved statistical significance on the primary endpoint of progression-free survival, without any detrimental effect on a secondary endpoint of overall survival. The treatment also led to a higher complete response rate and duration. \n</p>\n<p>\n  The test arm saw a similar rate of Grade 3 treatment emergent adverse events but a higher rate of Grade 5 TEAEs, serious adverse events, and side effects that led to study drug withdrawal. \n</p>\n<p>\n  \"In the context of a positive study, based on the totality of the data, we plan to discuss the benefit-risk profile of this combination with the U.S. FDA as we prepare for the planned supplemental biologics license application filing,\" Chief Executive Ameet Mallik said. \n</p>\n<p>\n  The company also said it will \"continue to evaluate a broad range of value maximizing alternatives,\" including near-term cost reductions. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2026 16:53 ET (20:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640841431","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640841431","pubTimestamp":1780519980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ADC Therapeutics plummeted after the company said it may pursue near-term cost cuts after reporting data from a Phase 3 trial of a lymphoma treatment.Shares fell 38% to $1.90 in after-hours trading Wednesday. The stock closed down 2.8% at $3.08, down 13% this year.The company said Zynlonta in combination with rituximab achieved statistical significance on the primary endpoint of progression-free survival, without any detrimental effect on a secondary endpoint of overall survival. The treatment also led to a higher complete response rate and duration.The test arm saw a similar rate of Grade 3 treatment emergent adverse events but a higher rate of Grade 5 TEAEs, serious adverse events, and side effects that led to study drug withdrawal.\"In the context of a positive study, based on the totality of the data, we plan to discuss the benefit-risk profile of this combination with the U.S. FDA as we prepare for the planned supplemental biologics license application filing,\" Chief Exec","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4539":"次新股","ADC":"艾格里房产","BK4139":"生物科技","ADCT":"ADC Therapeutics SA","BK4231":"零售房地产信托","BK4007":"制药","LENZ":"Therapeutics","BK4080":"零售业房地产投资信托"},"translate_title":"ADC Therapeutics股价因淋巴瘤药物试验数据和可能削减成本而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADCT":0.9,"LENZ":1.5,"ADC":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of ADC Therapeutics plummeted after the company said it may pursue near-term cost cuts after reporting data from a Phase 3 trial of a lymphoma treatment. \n\n\n  Shares fell 38% to $1.90 in after-hours trading Wednesday. The stock closed down 2.8% at $3.08, down 13% this year. \n\n\n  The company said Zynlonta in combination with rituximab achieved statistical significance on the primary endpoint of progression-free survival, without any detrimental effect on a secondary endpoint of overall survival. The treatment also led to a higher complete response rate and duration. \n\n\n  The test arm saw a similar rate of Grade 3 treatment emergent adverse events but a higher rate of Grade 5 TEAEs, serious adverse events, and side effects that led to study drug withdrawal. \n\n\n  \"In the context of a positive study, based on the totality of the data, we plan to discuss the benefit-risk profile of this combination with the U.S. FDA as we prepare for the planned supplemental biologics license application filing,\" Chief Executive Ameet Mallik said. \n\n\n  The company also said it will \"continue to evaluate a broad range of value maximizing alternatives,\" including near-term cost reductions. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2026 16:53 ET (20:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}